Investigation of the Efficacy and Safety of Concomitant Administration of Ciclesonide Nasal Spray and Azelastine Nasal Spray in Patients (18 Years or Older) With Perennial Allergic Rhinitis (PAR) Not Adequately Controlled on an Intranasal Corticosteroid or Antihistamine Monotherapy

NCT00806754 Phase 4 COMPLETED

* The primary objective of this study is to evaluate the efficacy of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray versus ciclesonide nasal spray alone in patients (18 years or older) with perennial allergic rhinitis (PAR) not adequately controlled on an intranasal corticosteroid or antihistamine monotherapy * The secondary objective is to investigate the safety of the concomitant administration of ciclesonide nasal spray and azelastine nasal spray

Details

Lead sponsor	AstraZeneca
Phase	Phase 4
Status	COMPLETED
Enrolment	340
Start date	2006-11
Completion	2007-08

Conditions

• Rhinitis, Allergic, Perennial

Interventions

• Ciclesonide nasal spray + placebo Azelastine
• Ciclesonide nasal spray + Azelastine

Primary outcomes

• Average of AM and PM patient-reported reflective Total Nasal Symptom Score (TNSS) over the four weeks of treatment — 4 weeks

Countries

United States